Ascrinvacumab
- Generic Name
- Ascrinvacumab
- Drug Type
- Biotech
- CAS Number
- 1463459-96-2
- Unique Ingredient Identifier
- 716FQ5REVO
- Background
Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- HCCHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Target Recruit Count
- 5
- Registration Number
- NCT05178043
- Locations
- ๐บ๐ธ
NYU Langone Health, New York, New York, United States
๐บ๐ธLos Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT01911273
- Locations
- ๐ฏ๐ต
Kinki University Hospital, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan
๐ฏ๐ตNational Cancer Center Hospital East, Kashiwa, Chiba, Japan
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
PF-03446962 in Relapsed or Refractory Urothelial Cancer
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Target Recruit Count
- 14
- Registration Number
- NCT01620970
- Locations
- ๐ฎ๐น
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 17
- Registration Number
- NCT01486368
- Locations
- ๐จ๐ฆ
CancerCare Manitoba, Winnipeg, Manitoba, Canada
๐จ๐ฆBCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
๐จ๐ฆCross Cancer Institute, Edmonton, Alberta, Canada
Asian Phase I Study Of PF-03446962
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT01337050
- Locations
- ๐ฏ๐ต
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
๐ฐ๐ทSeoul National University Hospital/Department of Internal Medicine, Seoul, Korea, Republic of
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT00557856
- Locations
- ๐บ๐ธ
Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States
๐ฎ๐นS.C Diagnostica Radiologica 2, Milano, Italy
๐ฎ๐นS.C. Chirurgia Generale Indirizzo Oncologico 1 (epato-gastro-pancreatica), Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.